• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Curevac N.V. (NQ: CVAC )

    2.760 +0.020 (+0.73%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 138,567
    Open 2.780
    Bid (Size) 2.720 (1)
    Ask (Size) 2.840 (2)
    Prev. Close 2.740
    Today's Range 2.760 - 2.830
    52wk Range 2.215 - 6.300
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
    Via ACCESSWIRE
    CureVac's CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress
    Via ACCESSWIRE

    Performance

    YTD
    -34.13%
    -34.13%
    1 Month
    -6.76%
    -6.76%
    3 Month
    -12.93%
    -12.93%
    6 Month
    -6.28%
    -6.28%
    1 Year
    -50.27%
    -50.27%

    More News

    Read More
    GSK Reveals 'Positive' Data From Mid-Stage Study Of Seasonal Influenza mRNA Vaccine
    Via Benzinga
    CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program
    Via ACCESSWIRE
    CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress
    Via ACCESSWIRE
    CVAC Stock Earnings: CureVac Misses EPS, Beats Revenue for Q2 2024
    Via InvestorPlace
    CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma
    Via ACCESSWIRE
    CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update
    Via ACCESSWIRE
    CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTech
    Via ACCESSWIRE
    CureVac Names Oncologist and Drug Development Expert Dr. Mehdi Shahidi to Supervisory Board
    Via ACCESSWIRE
    CVAC Stock Earnings: CureVac Misses EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    Southwest Airlines Adopts a Poison Pill Plan: 7 Things to Know
    Via InvestorPlace
    Why Is DouYu (DOYU) Stock Up 44% Today?
    Via InvestorPlace
    CureVac Layoffs 2024: What to Know About the Latest CVAC Job Cuts
    Via InvestorPlace
    Topics Workforce
    Exposures Layoff
    GSK and CureVac to Restructure Collaboration into New Licensing Agreement
    Via ACCESSWIRE
    GOEV Stock: Canoo Receives Fleet Order From Go2 Delivery
    Via InvestorPlace
    DM Stock Alert: Nano Dimension Is Scooping Up Desktop Metal for $183 Million
    Via InvestorPlace
    CVAC Stock Alert: CureVac Pops on Licensing Deal With GSK
    Via InvestorPlace
    GSK Buys Full Rights To Investigational Covid-19 And Influenza Vaccines From CureVac For Around $1.5B
    Via Benzinga
    Exposures COVID-19
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
    Via InvestorPlace
    CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities
    Via ACCESSWIRE
    CureVac Announces Voting Results of General Meeting
    Via ACCESSWIRE
    Why Quantum Shares Are Trading Lower By 45%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Via Benzinga
    First Human Death From Bird Flu Strain Puts Vaccine Stocks Back On The Map
    Via Benzinga
    Why Lands' End Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.